A pharmaceutical dosage form selected from the group consisting of tablets, pills, capsules, powders, granules, sterile parenteral solutions, parenteral suspensions, metered aerosol or liquid spray, drops, ampoules and suppositories comprising a compound of the formula (I)
- wherein
- R0 is selected from the group consisting of
- each RA and RB is independently selected from the group consisting of hydrogen and C1-4alkyl;
- each RC and RD is independently selected from the group consisting of hydrogen and C1-4alkyl;
- each RE is independently selected from the group consisting of hydrogen and C1-4alkyl;
- X is —NR1R2;
- each R1 and R2 is independently selected from the group consisting of hydrogen, C1-8alkyl, C1-8alkoxy, C1-8alkoxycarbonyl, cycloalkyl, cycloalkyl-C1-4alkyl, partially unsaturated carbocylyl, partially unsaturated carbocyclyl-C1-4alkyl, aryl, arC1-4alkyl, arC1-4alkoxy, —C(O)—C1-6alkyl, —C(O)-aryl, —C(O)-arC1-4alkyl, —C(O)O-cycloalkyl, —C(O)O-aryl, —C(O)O-arC1-4alkyl and —C(O)O-(partially unsaturated carbocyclyl);
- wherein the C1-8alkyl, cycloalkyl, partially unsaturated carbocyclyl, aryl or arC1-8alkyl group, whether alone or part of a substituent group, is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, C1-4alkyl, C1-4alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, —C(O)—C1-4alkyl, C1-4alkoxycarbonyl, N(RE)2, N(RE)2—C1-4alkyl, N(RE)—C(O)C(CH3)3, —C1-4alkyl-N(RE)—C(O)O—C1-4alkyl and —N(RE)—C(O)O—C1-4alkyl, aryl, aryloxy, cycloalkyl, heteroaryl, aryl substituted heteroarylaminosulfonyl or C1-6alkylthio;
- R3 is aryl;
- wherein the aryl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, C1-4alkyl, C1-4alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano or N(RE)2;
- n is an integer from 0 to 2;
- R4 is selected from the group consisting of hydroxy, C1-4alkyl and hydroxy substituted C1-4alkyl;
- m is an integer from 0 to 1;
- L1 is selected from the group consisting of C1-6alkyl and C3-6alkenyl;
- wherein the double bond of the C3-6alkenyl group is at least one carbon atom removed from the attachment point to the N atom;
- and wherein the C1-6alkyl or C3-6alkenyl group is optionally substituted with one to two substituents independently selected from hydroxy, fluoro, C1-6alkyl, fluorinated C1-6alkyl or C1-6alkoxy;
- is selected from the group consisting of phenyl, naphthyl and acenaphthyl;
- p is an integer from 0 to 5;
- R5 is selected from the group consisting of hydroxy, carboxy, halogen, C1-6alkyl, hydroxy substituted C1-6alkyl, C1-6alkoxy, nitro, cyano, NR1R2, trifluoromethyl, trifluoromethoxy, C1-4alkoxycarbonyl, —SO—NR1R2, —SO2—NR1R2 and —C(O)—NR1R2;
- q is 0;
- R6 selected from the group consisting of -(L2)0-1-R7;
- L2 is selected from the group consisting of —C1-6alkyl-, -C2-4alkenyl-, -C2-6alkynyl-, —O—, —S—, —NH—, —N(C1-4alkyl)-, —C1-6alkyl-O—, —C1-6alkyl-S—, —O—C1-6alkyl-, —S—C1-6alkyl-, —O—C2-6alkyl—O—, —S—C2-6alkyl-S—, —SO2—, —SO2NH—, —SO2N(C1-4alkyl)-, —NH—SO2—, —N(C1-4alkyl)-SO2—, —C(O)—O— and —O—C(O)—;
- R7 is selected from the group consisting of aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl and heterocycloalkyl;
- wherein the aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from hydroxy, carboxy, halogen, C1-6alkyl, C1-6alkoxy, nitro, cyano, N(RE)2, trifluoromethyl, trifluoromethoxy, C1-4alkoxycarbonyl, —SO2—N(RE)2 and —C(O)—N(RE)2;
- or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.